◆ 会议时间：2021年12月8日至11日
◆ 会议地点：瑞士 日内瓦/Geneva, Switzerland

◆ 会议简介：

2021年ESMO免疫肿瘤学大会将于2021年12月8日至11日在瑞士日内瓦举行，会议由欧洲肿瘤内科学会（ESMO）组织。ESMO免疫肿瘤学大会是一个全球性会议，从免疫疗法的基础知识到最新的研究结果；从了解不同的治疗方案到毒性的管理和最新数据的解读，ESMO免疫肿瘤学大会将满足对癌症治疗这一热门领域感兴趣的肿瘤学利益相关者的不同需求。

欧洲肿瘤内科学会（ESMO）成立于1975年，是全球领先的肿瘤内科学专业组织。ESMO是肿瘤学教育和信息的参考学会，现在全球160多个国家和地区拥有超过25,000余名会员；ESMO致力于通过宣促进多学科的癌症护理，支持肿瘤学家的专业发展以及在全球倡导可持续的癌症护理，尽而为癌症患者提供最佳的护理。——未经本站许可，禁止复制转载摘录镜像本站任何内容-领域国际医学会议网。

ESMO Immuno-Oncology Congress

DATE: 8-11 Dec 2021
VENUE: Geneva, Switzerland

摘要提交-Abstract submission

Abstract submission deadlines

Outcome notifications

Outcome notifications are expected to be made available to first authors by mid-October 2021.

Late-breaking abstracts

*A skeleton indicating the type of data that will be available by the late-breaking abstract deadline must be submitted online by the regular abstract deadline (29 September 2021).

Final versions must be submitted by 3 November 2021, 21:00 CEST (Central European Time).

Late-breaking abstracts may be submitted for high quality, new research findings from randomised phase II or phase III trials with implications for clinical practice or understanding of disease processes. 

Only abstracts for which no conclusive data are available at the time of the abstract submission deadline of 29 September 2021 will be considered for late-breaking status. The work must not have been previously published in any publication in a peer review setting or presented at a meeting of any other scientific organisation prior to ESMO Immuno-Oncology Congress 2021, and a pre-planned analysis must be scheduled between the regular submission deadline of 29 September 2021 and the late-breaking submission deadline of 3 November 2021.

Trial in Progress abstracts

Trial in Progress (TiP) abstracts in all phases of clinical research (phases I to III) may be submitted to the ESMO Immuno Oncology Congress 2021.

It is expected that abstracts submitted as Trial in Progress are ongoing trials that have not reached any protocol-specified endpoints for analysis and consequently will only require the completion of two (2) sections:

• Background
• Trial design

Notes:

• Recruitment must have already begun or have been completed by the abstract submission deadline of 29 September 2021.
• Abstracts including results or preliminary data will be rejected.
• Trial in Progress abstracts will not be considered for Proffered Paper (oral) presentation or Mini Oral.
• Encore TiP abstracts will be rejected.
• Trial in Progress (TiP) abstracts will be reviewed by the ESMO Immuno-Oncology Congress 2021 Scientific Committee and considered on the merits of the scientific and clinical rationale of the trial.

Presentation of accepted abstracts

The ESMO Immuno-Oncology Congress 2021 Scientific Committee will select abstracts for presentation during the Congress based on the following possibilities:

• Proffered Paper – Oral presentations by authors presenting original data of superior quality, followed by expert discussion and perspectives.
• Mini Oral – Short oral presentations by authors presenting data of good quality, followed by expert discussion and perspectives.
• Poster – Display sessions for review, discussion and questions. Posters will be displayed for one day of the Congress and the presenting authors must be available for Q&A for one hour to represent their work.

All accepted abstracts, including Late-breaking, will be published online only in the ESMO Immuno-Oncology Congress 2021 Abstract Book, a supplement to the official ESMO journal, Annals of Oncology.

Detailed instructions for the preparation of presentations and posters will be made available on the ESMO website by end October 2021 along with scheduling notices.

Publications

All accepted abstracts will be published as a supplement to the official ESMO journal Annals of Oncology.

注册费：

◆ 参会对象：：医生、医院科室主任/副主任、住院医师、医院管理者、医护人员以及从事该领域研究的科学家、研究人员、医药企业代表等等。